Comparing the current results to its competitors, Serina Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 4.85 %, recorded in the same quarter.
Serina Therapeutics Inc , slower than the average decrease reported by the company's competitors of -75.84 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -75.84 %
Serina Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes large and specialty pharmaceutical, biopharmaceutical, and biotechnology firms, as well as academic research institutions, governmental agencies, and both public and private research organizations. Competitors engage in technology development and product candidate advancement. Some smaller biotechnology companies collaborate with larger established firms to support research, development, commercialization, or to combine treatment approaches aimed at creating longer-lasting or more effective therapies that may compete with the company's products. The company expects competition to increase with the emergence of new therapies, technologies, and data, particularly in drug delivery and central nervous system (CNS) disorder treatments. Numerous commercial and academic preclinical studies and clinical trials are ongoing in the CNS field. Orphan drug exclusivity can prevent approval of competing products for seven years if granted first to a competitor, although this exclusivity may not provide complete protection from competition.
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
Sources:
Serina Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Serina Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
